EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy

Ellen Reusch, Keng Hee Peh, Rachael Morgan, Harry Momo, David Orren, Stephanie Rock, Thomas Pittman, Janna Neltner, Jill Kolesar, John Villano

Frontiers in Oncology · 22.10.2025 · 15

DOI: 10.3389/fonc.2025.1587752 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 22.10.2025. Verfasst von Ellen Reusch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Markey Cancer Center, University of Kentucky, Lexington, KY, United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningiomas are the most common primary tumor in the central nervous system, yet an effective systemic treatment remains a challenge. We present a grade 2 meningioma that resulted in a positive and prolonged response to pembrolizumab. Our case had polybromo-1 ( PBRM1 ) and BAP1 functional loss, tumor mutational burden of 4 Muts/Mb, stable microsatellite status, and a PD-L1 tumor proportion score of <1%. We add to the limited literature regarding PBRM1 mutations in meningiomas. We discuss our findings in relation to the ongoing investigation of immune checkpoint inhibitor therapy in treating higher-grade refractory meningiomas.

Schlagwörter

Stichwörter der Autor:innen

PBRM1PD-1/L1atypical meningiomagrade 2 meningiomaimmunotherapy

Autor:innen und Institutionen

  • Markey Cancer Center, University of Kentucky, Lexington, KY, United States.
  • College of Pharmacy, University of Kentucky, Lexington, KY, United States.
  • College of Medicine, University of Kentucky, Lexington, KY, United States.
  • Molecular Science Liaison Group, Caris Life Sciences, Phoenix, AZ, United States.
  • Department of Neurosurgery, University of Kentucky, Lexington, KY, United States.
  • Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, United States.

Förderung

  • National Institutes of Health

Zitieren

APA

Reusch, E., Peh, K. H., Morgan, R., Momo, H., Orren, D., Rock, S., Pittman, T., Neltner, J., Kolesar, J., & Villano, J. (2025). Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1587752

Vancouver

Reusch E, Peh KH, Morgan R, Momo H, Orren D, Rock S, et al. Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1587752

BibTeX
@article{Reusch2025,
  author = {Reusch, Ellen and Peh, Keng Hee and Morgan, Rachael and Momo, Harry and Orren, David and Rock, Stephanie and Pittman, Thomas and Neltner, Janna and Kolesar, Jill and Villano, John},
  title = {Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1587752}
}
Kostenlos starten →